New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - gabapentin 400mg - capsule - 400 mg - active: gabapentin 400mg excipient: gelatin   iron oxide red   iron oxide yellow   lactose monohydrate maize starch purified talc purified water   sodium laurilsulfate   titanium dioxide   - ipca-gabapentin is indicated for the treatment of neuropathic pain in adults over 18 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - propranolol hydrochloride, quantity: 40 mg - tablet - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; sodium starch glycollate; brilliant blue fcf aluminium lake; sunset yellow fcf aluminium lake; quinoline yellow; povidone - angina pectoris; hypertension; prevention of migraine; cardiac dysrhythmias: certain intrinsic cardiac dysrhythmias; dysrhythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug-induced dysrhythmias (eg tachycardia due to digitalis or adrenaline overdosage); essential tremor, including familial and senile tremor; phaeochromocytoma (only with concurrent alpha-receptor blockade); hypertrophic subaortic stenosis; suspected or definite myocardial infarction; fallot?s tetralogy

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - propranolol hydrochloride, quantity: 10 mg - tablet - excipient ingredients: sunset yellow fcf aluminium lake; povidone; lactose monohydrate; maize starch; magnesium stearate; quinoline yellow; sodium starch glycollate - angina pectoris; hypertension; prevention of migraine; cardiac dysrhythmias: certain intrinsic cardiac dysrhythmias; dysrhythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug-induced dysrhythmias (eg tachycardia due to digitalis or adrenaline overdosage); essential tremor, including familial and senile tremor; phaeochromocytoma (only with concurrent alpha-receptor blockade); hypertrophic subaortic stenosis; suspected or definite myocardial infarction; fallot?s tetralogy

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; hypromellose; stearic acid; colloidal anhydrous silica - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; macrogol 400; hyprolose; polysorbate 80; titanium dioxide; hypromellose; sodium starch glycollate type a; microcrystalline cellulose - treatment of children aged 6 years and older and adolescents with obsessive compulsive disorder. ,treatment of major depression, obsessive compulsive disorder and panic disorder in adults. treatment of social phobia (social anxiety disorder) and the prevention of its relapse in adults.,treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; magnesium stearate; hypromellose; titanium dioxide; sodium starch glycollate type a; polysorbate 80; hyprolose; macrogol 400 - treatment of children aged 6 years and older and adolescents with obsessive compulsive disorder. ,treatment of major depression, obsessive compulsive disorder and panic disorder in adults. treatment of social phobia (social anxiety disorder) and the prevention of its relapse in adults.,treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose; croscarmellose sodium; lactose monohydrate; macrogol 400; pregelatinised maize starch; titanium dioxide; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; purified talc; colloidal anhydrous silica - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hypromellose; magnesium stearate; iron oxide red; croscarmellose sodium; macrogol 400; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; pregelatinised maize starch - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.